Mraz Amerine & Associates Inc. Grows Stake in Johnson & Johnson $JNJ

Mraz Amerine & Associates Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 17.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,451 shares of the company’s stock after purchasing an additional 4,209 shares during the quarter. Johnson & Johnson makes up approximately 0.7% of Mraz Amerine & Associates Inc.’s portfolio, making the stock its 22nd biggest position. Mraz Amerine & Associates Inc.’s holdings in Johnson & Johnson were worth $4,346,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $48,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson during the first quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on JNJ shares. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Royal Bank Of Canada upped their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. HSBC lifted their target price on Johnson & Johnson from $188.00 to $210.00 in a research note on Tuesday, September 30th. Finally, Bank of America upped their price target on Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $189.88.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.5%

Johnson & Johnson stock opened at $189.75 on Thursday. The stock’s 50 day moving average price is $177.49 and its 200 day moving average price is $163.37. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $190.22. The company has a market cap of $456.98 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 2.41 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the company earned $2.82 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.